NEW YORK (GenomeWeb) – Mbio Diagnostics today announced a product development and licensing agreement with Roka Bioscience.

The partnership will join MBio's multiplex, point-of-care diagnostics technology with Roka's solutions for food safety testing. The agreement covers "certain exclusive and non-exclusive fields," the firms said in a statement. Boulder, Colorado-based MBio and Warren, New Jersey-based Roka said they will jointly carry out product development.

Financial and other terms of the agreement were not disclosed.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Oxford Nanopore Technologies is looking into dual listings in London and Hong Kong, according to the South China Morning Post.

The New York Times looks into medical research funding in the US and how the grant system might not be funding the best work.

US lawmakers proposed increasing the National Science Foundation budget, including its facilities account, Science reports.

In PNAS this week: effects of gene deletions on bacterial metabolic networks, genetic responses to sea star wasting disease, and more.